EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Regulation FD DisclosureItem 7.01
On September 11, 2017, EyeGate Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company has formally launched a social media presence on Facebook, Twitter and LinkedIn. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished to Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
| Item 7.01. | Financial Statements and Exhibits. |
The Company hereby furnishes the following exhibit:
| 99.1 | Press Release of the Company, dated as of September 11, 2017. |
EYEGATE PHARMACEUTICALS INC ExhibitEX-99.1 2 v474897_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 EyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships WALTHAM,…To view the full exhibit click here
About EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG)
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
